- Home
- PLL vs NLSP Comparison
PLL vs NLSP Comparison
Compare PLL & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLL
- NLSP
- Stock Information
- Founded
- PLL 2016
- NLSP 2015
- Country
- PLL United States
- NLSP Switzerland
- Employees
- PLL N/A
- NLSP N/A
- Industry
- PLL Other Metals and Minerals
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- PLL Basic Materials
- NLSP Health Care
- Exchange
- PLL Nasdaq
- NLSP Nasdaq
- Market Cap
- PLL 238.0M
- NLSP 243.8M
- IPO Year
- PLL 2017
- NLSP 2021
- Fundamental
- Price
- PLL $11.68
- NLSP $3.13
- Analyst Decision
- PLL Buy
- NLSP
- Analyst Count
- PLL 8
- NLSP 0
- Target Price
- PLL $22.63
- NLSP N/A
- AVG Volume (30 Days)
- PLL 905.3K
- NLSP 624.8K
- Earning Date
- PLL 11-12-2024
- NLSP 11-22-2024
- Dividend Yield
- PLL N/A
- NLSP N/A
- EPS Growth
- PLL N/A
- NLSP N/A
- EPS
- PLL N/A
- NLSP N/A
- Revenue
- PLL $46,981,000.00
- NLSP N/A
- Revenue This Year
- PLL $155.85
- NLSP N/A
- Revenue Next Year
- PLL $13.29
- NLSP N/A
- P/E Ratio
- PLL N/A
- NLSP N/A
- Revenue Growth
- PLL N/A
- NLSP N/A
- 52 Week Low
- PLL $6.57
- NLSP $3.00
- 52 Week High
- PLL $31.82
- NLSP $29.08
- Technical
- Relative Strength Index (RSI)
- PLL 47.28
- NLSP 30.46
- Support Level
- PLL $11.12
- NLSP $3.56
- Resistance Level
- PLL $14.60
- NLSP $4.15
- Average True Range (ATR)
- PLL 1.19
- NLSP 0.46
- MACD
- PLL -0.21
- NLSP -0.05
- Stochastic Oscillator
- PLL 16.09
- NLSP 7.47
About PLL Piedmont Lithium Inc.
Piedmont Lithium Inc, is a U.S. based, development-stage, multi-asset, integrated lithium business in support of a clean energy economy and U.S. and world-wide energy security. Its portfolio of wholly-owned projects includes Carolina Lithium, a proposed fully integrated spodumene ore-to-lithium hydroxide project in Gaston County, North Carolina, and Tennessee Lithium, a proposed merchant lithium hydroxide manufacturing plant in McMinn County, Tennessee.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.